GERMANTOWN, Md. and GUANGZHOU, China, April 27, 2023 /PRNewswire/ — RNAimmune, Inc. (the “Company” or “RNAimmune”), a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, today announced that the Company has received a clearance…
